title: Biologic Therapy in Inflammatory and Immunomediated Skin Diseases: Safety Profile.
abstract: Biologic treatments have modified the therapeutic armamentarium in the treatment of many dermatological and non- dermatological diseases and data on literature have widely focused on the efficacy and safety of TNF-alpha inhibitors in psoriasis. Although the etiopathogenesis has not completely elucidated, inflammation appears the lait motif unifying the immune-pathogenesis of diverse skin disease, as atopic dermatitis, alopecia areata and hidradenitis suppurativa. Actually, data on the off-label use of biologics in cutaneous immune-mediated inflammatory diseases are scarce and restricted to anecdotal cases and case series. The present review aims to evidence the major off- label use of TNF-alpha inhibitors in dermatology.
authors.affiliation: Dermatologic Clinic, Polytechnic University of Marche Region, Ancona, Via Conca, 71, 60126 Ancona, Italy. giulia.ganzetti@alice.it.
authors.forename: Giulia
authors.initials: G
authors.lastname: Ganzetti
authors.forename: Anna
authors.initials: A
authors.lastname: Campanati
authors.forename: E
authors.initials: E
authors.lastname: Molinelli
authors.forename: A
authors.initials: A
authors.lastname: Offidani
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use; D000818:Animals; D001691:Biological Therapy / Q000009:adverse effects / Q000379:methods*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis / Q000209:etiology / Q000276:immunology; D017497:Hidradenitis Suppurativa / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors / Q000276:immunology*; D056687:Off-Label Use; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D012871:Skin Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology*
chemical_list: D018836:Inflammation Mediators; D000068879:Adalimumab